文献速递肝病

无肝硬化丙型肝炎病毒基因1-6型患者接受8周和12周格卡瑞韦/哌仑他韦治疗的SVR12率高:一项整合分析

High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis.
PubMed 文献 · J Hepatol · 2018-03-16

该整合分析汇总9项II/III期试验,纳入2041例无肝硬化的慢性HCV基因1-6型患者,接受格卡瑞韦/哌仑他韦治疗8周或12周。8周组SVR12为98%(943/965),12周组为99%(1060/1076),差异无统计学意义(p=0.2)。结论认为8周为无肝硬化患者的最佳治疗时长。

要点

  • 无肝硬化HCV基因1-6型患者接受格卡瑞韦/哌仑他韦8周治疗,总体SVR12达98%。
  • 8周组与12周组SVR12差异无统计学意义(p=0.2)。
  • 基线因素相关亚组分析中SVR12率均>95%。

核心结论

  • 无肝硬化的慢性HCV基因1-6型患者接受格卡瑞韦/哌仑他韦8周治疗总体SVR12率为98%,不受基线患者或病毒特征影响。
  • 延长4周治疗未显著提高SVR12率,表明该人群最佳治疗时长为8周。

研究设计与样本

  • 整合分析汇总9项II期和III期临床试验,纳入无肝硬化的慢性HCV基因1-6型感染患者,接受格卡瑞韦/哌仑他韦(300 mg/120 mg)治疗8周或12周。
  • 患者为初治或经聚乙二醇干扰素、利巴韦林和/或索磷布韦治疗失败者;所有HCV基因3型患者均为初治。
  • 分析共纳入2041例无肝硬化患者。

主要发现

  • 意向治疗人群中,8周组943/965例(98%)获得SVR12,12周组1060/1076例(99%)获得SVR12,率差无统计学意义(p=0.2)。
  • 亚组分析显示,传统上与较低疗效相关的基线因素各亚组SVR12率均>95%。
  • 格卡瑞韦/哌仑他韦耐受性良好,1例(<0.1%)发生直接抗病毒药物相关严重不良事件;3级实验室异常罕见。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Glecaprevir plus pibrentasvir (G/P) is a pangenotypic, once-daily, ribavirin-free direct-acting antiviral (DAA) treatment for hepatitis C virus (HCV) infection. In nine phase II or III clinical trials, G/P therapy achieved rates of sustained virologic response 12 weeks after treatment (SVR12) of 93-100% across all six major HCV genotypes (GTs). An integrated efficacy analysis of 8- and 12-week G/P therapy in patients without cirrhosis with HCV GT 1-6 infection was performed. METHODS: Data were pooled from nine phase II and III trials including patients with chronic HCV GT 1-6 infection without cirrhosis who received G/P (300 mg/120 mg) for either 8 or 12 weeks. Patients were treatment naïve or treatment experienced with peginterferon, ribavirin, and/or sofosbuvir; all patients infected with HCV GT 3 were treatment naïve. Efficacy was evaluated as the SVR12 rate. RESULTS: The analysis included 2,041 patients without cirrhosis. In the intent-to-treat population, 943/965 patients (98%) achieved SVR12 when treated for eight weeks, and 1,060/1,076 patients (99%) achieved SVR12 when treated for 12 weeks; the difference in rates was not significant (p = 0.2). A subgroup analysis demonstrated SVR12 rates > 95% across baseline factors traditionally associated with lower efficacy. G/P was well tolerated, with one DAA-related serious adverse event (<0.1%); grade 3 laboratory abnormalities were rare. CONCLUSIONS: G/P therapy for eight weeks in patients with chronic HCV GT 1-6 infection without cirrhosis achieved an overall SVR12 rate of 98% irrespective of baseline patient or viral characteristics; four additional weeks of treatment did not significantly increase the SVR12 rate, demonstrating that the optimal treatment duration in this population is eight weeks. LAY SUMMARY: In this integrated analysis of nine clinical trials, patients with chronic HCV genotype 1-6 infection without cirrhosis were treated for either 8 or 12 weeks with the direct-acting antiviral regimen glecaprevir/pibrentasvir (G/P). The cure rate was 98% and 99% following 8 and 12 weeks of treatment, respectively; the difference in rates was not significant (p = 0.2), nor was there a significant difference in the cure rates across the two treatment durations on the basis of baseline patient or viral characteristics. These results, along with a favourable safety profile, indicate that G/P is a highly efficacious and well-tolerated pangenotypic eight-week therapy for most patients with chronic HCV infection.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Puoti M, Foster GR, Wang S, et al. High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis. J Hepatol. 2018. PMID: 29551706. doi:10.1016/j.jhep.2018.03.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。